1. Home
  2. OFS vs ACET Comparison

OFS vs ACET Comparison

Compare OFS & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OFS Capital Corporation

OFS

OFS Capital Corporation

HOLD

Current Price

$3.86

Market Cap

46.2M

Sector

Finance

ML Signal

HOLD

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$8.25

Market Cap

77.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OFS
ACET
Founded
2001
1947
Country
United States
United States
Employees
47
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
46.2M
77.3M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
OFS
ACET
Price
$3.86
$8.25
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$48.33
AVG Volume (30 Days)
56.8K
135.2K
Earning Date
04-30-2026
05-06-2026
Dividend Yield
16.83%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$17.44
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.72
$0.46
52 Week High
$9.31
$9.05

Technical Indicators

Market Signals
Indicator
OFS
ACET
Relative Strength Index (RSI) 50.42 59.78
Support Level $3.57 $6.28
Resistance Level $4.40 $8.46
Average True Range (ATR) 0.23 0.49
MACD -0.00 0.00
Stochastic Oscillator 37.18 73.27

Price Performance

Historical Comparison
OFS
ACET

About OFS OFS Capital Corporation

OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to provide its stockholders with both current income and capital appreciation through debt investments and, to a lesser extent, equity investments.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

Share on Social Networks: